COMPASS Success Reinforces J&J/Bayer's Broad Labeling Strategy For Xarelto
Executive Summary
J&J will be talking to FDA regarding expanded approval for peripheral arterial disease and coronary artery disease following early stop of COMPASS outcomes study; strong data will be needed if asymptomatic patients are targeted.
You may also be interested in...
Keeping Track: Xarelto Earns CV Risk Reduction Claim In Quiet Week; Spotlight On Formal Dispute Resolution
Latest drug development news and highlights from our US FDA Performance Tracker
ESUS Fails But Hurt Minimal for Bayer/Janssen's Xarelto
Bayer and Janssen's bid for NOAC dominance through diversification has hit a buffer with the failure of a Phase III trial in stroke, but the indication is small and not expected to hit sales that much.
Portola's AndexXa Antidote For Xarelto And Eliquis Finally On The Way
FDA approval of an antidote for Factor Xa novel anticoagulants would further drive the already strong uptake of J&J/Bayer's Xarelto and Bristol/Pfizer's Eliquis, analysts say.